Phenotypic and Functional Analysis of Immune Cell Subsets in Pediatric-onset Multiple Sclerosis (MS): Towards Definition of Earliest Disease Mechanisms (P2.236)

CONCLUSION: Our findings selectively implicate CD4+CCR2+CCR5+ and CD8+CD161high MAIT T cell subsests in early pediatric-onset MS pathophysiology, but not in pediatric monophasic CNS inflammatory conditions.Disclosure: Dr. Nyirenda has nothing to disclose. Dr. Li has nothing to disclose. Dr. Moore has nothing to disclose. Dr. Rozenberg has nothing to disclose. Dr. Rezk has nothing to disclose. Dr. Johnson has nothing to disclose. Dr. Sadovnick has received personal compensation for activities with Biogen Idec, Merck Serono, Teva Neuroscience, and Bayer Pharmaceuticals Corp. Dr. Arnold has received personal compensation for activities with Acorda Therapeutics, Bayer Pharmaceuticals Corporation, Biogen Idec, Coronado Biosciences, EMD Serono, Genentech Inc., Genzyme Corporation, GlaxoSmithKline Inc., MedImmune, NeuroRx Research. Dr. Arnold has received research support from Bayer Pharmaceuticals Corporation. Dr. Marrie has received research support from the Canadian Institutes of Health Research, Multiple Sclerosis Society of Canada, Consortium of MS Centers, and Sanofi-Aventis Pharmaceuticals, Inc. Dr. Banwell has received personal compensation in an editorial capacity for Multiple Sclerosis and Related Disorders. Dr. Banwell's institution has received research support from the Multiple Sclerosis Society of Canada, the Canadian Multiple Sclerosis Scientific Research Foundation, and Canadian Institute of Health Research. Dr. Bar-Or has received personal compensation for activitie...

Source: Neurology - April 9, 2014 Category: Neurology Authors: Nyirenda, M., Li, R., Moore, C., Rozenberg, A., Rezk, A., Johnson, T., Sadovnick, D., Arnold, D., Marrie, R.-A., Banwell, B., Bar-Or, A. Tags: Pediatric Multiple Sclerosis and Other Demyelinating Diseases Source Type: research